InvestorsHub Logo
Followers 13
Posts 3218
Boards Moderated 0
Alias Born 04/26/2007

Re: None

Thursday, 01/13/2022 1:07:02 AM

Thursday, January 13, 2022 1:07:02 AM

Post# of 40492
Jefferies analyst Roger Song assumed coverage of Inovio Pharmaceuticals with a Hold rating and price target of $6, down from $8. The analyst believes near-term stock movement will likely be driven by the company's COVID-19 program and he's cautious on the Phase 3 efficacy results in the first half of 2022. He's watching for the second Phase 3 precancerous cervical dysplasia data including biomarker results in 2022 to further assess potential uptake.

Read more at:
https://thefly.com/n.php?id=3432608
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INO News